Investment advisor Morgan Stanley continued its coverage of Sigilon Therapeutics (NASDAQ:SGTX) on May 26, 2023, recommending that investors hold on to their shares with an Equal-Weight ranking.
Stock Price Forecast Indicates 22.59% Decrease
The average one-year target price for SGTX as of May 11, 2023 is $4.34, according to market data provider Fintel. Expert projections range from $2.02 to $7.35. If the average target is reached, it will represent a 22.59% decrease from the company’s most recent closing share price of $5.60.
To compare the potential returns of SGTX with those of other companies, please see Fintel’s leaderboard of firms showing the highest and lowest potential return rates.
Fintel predicts that Sigilon Therapeutics will earn $11 million in annual revenue, which represents a decrease of 23.34%. Non-GAAP earnings per share (EPS) are projected at -$1.29.
How Do the Funds Feel About SGTX?
No. of funds or institutions owning Sigilon Therapeutics shares is 53, according to Fintel. This data has remained constant during the last quarter. The average portfolio weight dedicated to SGTX for all funds is 0.01%, an increase of 117.46%. Institutional investors’ total shares in the company have increased 1.19% over the past three months to 17,844K shares. SGTX’s put/call ratio is currently 0.20, indicating a bullish sentiment.
What Are the Other Major Shareholders Doing?
Among those owning stakes in the company, Flagship Pioneering is the largest shareholder and holds 10,370K shares or 31.88% ownership of the company. This represents no change over the past quarter. Canada Pension Plan Investment Board holds 1,485K shares (4.57%), followed by Cercano Management with 885K shares (2.72%) and Harbourvest Partners with 741K shares (2.28%). BlackRock Health Sciences Trust II holds 565K shares (1.74%). None of these major shareholders have made changes in the last quarter.
About Sigilon Therapeutics (As provided by the company)
Sigilon Therapeutics aims to cure chronic diseases through its Shielded Living Therapeutics™ platform. Its non-viral engineered cell-based therapies are designed to produce important proteins, enzymes or factors needed by individuals living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. Sigilon’s patented Afibromer™ biomaterials matrix protects these engineered cells from immune rejection and fibrosis. Flagship Pioneering, Daniel Anderson, Ph.D., and Robert Langer, Sc.D., were among Massachusetts Institute of Technology scientists who founded Sigilon.
To access filings and other information about Sigilon Therapeutics, please visit Fintel.
The author’s opinions and views do not necessarily reflect those of Nasdaq, Inc.
